Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 30

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 30
---
 time from the date of effectiveness of the registration statement
of which this prospectus forms a part until a Termination Event.

The purchase price for Depositary
Shares that we may sell to the Selling Shareholder under the Purchase Agreement will fluctuate based on the trading price of shares of
our Depositary Shares. Depending on market liquidity at the time, sales of Depositary Shares may cause the trading price of Depositary
Shares to decrease. We generally have the right to control the timing and amount of any future sales of Depositary Shares to the Selling
Shareholder. Additional sales of Depositary Shares, if any, to the Selling Shareholder will depend upon market conditions and other factors
to be determined by us. We may ultimately decide to sell to the Selling Shareholder all, some or none of the additional Depositary Shares
that may be available for us to sell pursuant to the Purchase Agreement. If and when we do sell Depositary Shares to the Selling Shareholder,
after the Selling Shareholder has acquired Depositary Shares, the Selling Shareholder may resell all, some or none of Depositary Shares
at any time or from time to time in its discretion and at different prices. Therefore, sales to the Selling Shareholder by us could result
in substantial dilution to the interests of other holders of Depositary Shares. In addition, if we sell a substantial number of shares
of our Depositary Shares to the Selling Shareholder under the Purchase Agreement, or if investors expect that we will do so, the shares
held by the Selling Shareholder will represent a significant portion of our public float and may result in substantial decreases to the
price of our Depositary Shares. The actual sales of Depositary Shares or the mere existence of our arrangement with the Selling Shareholder
may also make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might
otherwise wish to effect such sales.

| 16 |

In addition, Depositary Shares
issuable upon exercise or vesting of incentive awards under our incentive plans are, once issued, eligible for sale in the public market,
subject to any lock-up agreements and, in some cases, limitations on volume and manner of sale applicable to affiliates under Rule 144.
Furthermore, Depositary Shares reserved for future issuance under our incentive plan may become available for sale in future.

As of January 15, 2025, we
also had 770,026 outstanding warrants (including pre-funded warrants) exercisable for